Blood Test May Predict Chemotherapy Outcomes in Germ Cell Tumors

For the roughly one in ten young adults with germ cell tumors whose cancers do not respond to standard chemotherapy, clinicians face a stark choice: escalate to high-dose chemotherapy - a punishing treatment with its own serious risks - or accept that standard regimens have failed. A study published in the Journal of Clinical Oncology suggests that fragments of tumor DNA circulating in the blood could help guide that decision with more precision than current tools allow.

The research, conducted by the Looijenga group at the Princess Maxima Center for Pediatric Oncology in the Netherlands in collaboration with scientists from Italy and Slovakia, analyzed blood samples from 69 patients receiving high-dose chemotherapy and 26 patients receiving standard chemotherapy. All participants were young adults with relapsed or refractory germ cell tumors - cancers arising from the precursor cells that normally develop into sperm or eggs.

What the Blood Revealed

The team focused on circulating cell-free DNA (cfDNA), genetic material shed by tumor cells into the bloodstream. Using a technique called shallow whole genome sequencing, they assessed two specific characteristics: tumor fraction (the proportion of cfDNA originating from cancer cells) and copy number alterations (structural changes in chromosomes that signal cancer activity).

Tumor fraction exceeded the detection threshold in 75% of patients treated with high-dose chemotherapy, confirming that tumor DNA was detectable at measurable levels in most cases. Critically, patients with high tumor fraction had significantly worse progression-free and overall survival compared to those with low or undetectable tumor fraction - a pattern observed in both the high-dose and standard-dose groups.

Specific chromosomal changes also proved informative. Gains on chromosomal regions 3p, 9q, and 11q, along with losses on 6q, appeared more frequently in patients with poor outcomes in the high-dose cohort. Tumors with what pathologists describe as extra-embryonic histology - specifically yolk sac tumor and choriocarcinoma subtypes, identified by their distinct appearance under the microscope - carried a particularly poor prognosis when these alterations were present.

Comparing Against an Existing Marker

The researchers also tested an established biomarker, a small RNA molecule called miR-371a-3p, which is currently used to detect germ cell tumor activity. While miR-371a-3p proved more sensitive than cfDNA analysis at detecting the presence of disease, it did not predict survival as effectively. The two approaches appear to measure different things: one excels at detecting whether cancer is present, the other at forecasting how patients will fare.

A secondary finding from the data suggests that high-dose chemotherapy may be more effective than standard chemotherapy specifically in patients who have high tumor fraction - a potentially useful distinction for oncologists trying to identify which patients are most likely to benefit from escalated treatment.

Context: Who Gets Germ Cell Tumors

Germ cell tumors arise from the precursor cells responsible for producing eggs or sperm. They occur predominantly in boys and young men, developing primarily in the testes but sometimes in other body sites. Testicular cancer is the most common malignancy in men aged 15 to 35. In the Netherlands alone, approximately 850 young men are diagnosed with testicular germ cell tumors each year, alongside roughly 30 children diagnosed with germ cell tumors overall.

Standard chemotherapy cures most patients. But in those 10% for whom it fails, the prognosis is grim: despite high-dose chemotherapy, approximately half ultimately die. The lack of reliable tools to predict who will respond to escalated treatment leaves oncologists making decisions based on incomplete information, often in circumstances where time and the patient's remaining quality of life are both precious resources.

Minimally Invasive, Practically Relevant

What makes cfDNA analysis attractive as a clinical tool is its relative simplicity. Blood draws are far less invasive than tissue biopsies and can be performed repeatedly across a treatment course. The ability to sample tumor DNA before and during chemotherapy offers a dynamic window into how a cancer is responding - or failing to respond - in real time.

The study's authors suggest these biomarkers could support two related goals: refining risk stratification so that clinicians better understand a patient's prognosis before committing to high-dose chemotherapy, and identifying patients for whom alternative treatment targets should be explored, since current salvage options remain inadequate for many.

Limitations and What Comes Next

The findings come with meaningful caveats. The study enrolled 95 patients across Italian and Slovakian hospitals - a sample large enough to identify patterns but small enough that the results need external confirmation. The cohort consisted entirely of young adults, and whether the same cfDNA markers predict outcomes in children with germ cell tumors remains unknown. The retrospective nature of the analysis also means that confounding variables cannot be fully excluded.

The researchers have outlined a clear next step: validating the findings in a larger international cohort that includes adolescents and children. If those results hold, the cfDNA approach could move toward clinical use - giving oncologists a concrete tool to determine whether initiating intensive chemotherapy is likely to benefit a specific patient, or whether resources and effort would be better directed toward experimental or palliative approaches.

The research was funded by Stichting Kinderen Kankervrij (KiKa) and the Italian Ministry of Health. The study was led by Prof. Dr. Leendert Looijenga at the Princess Maxima Center, with senior collaborators Prof. Dr. Migal Mego at Comenius University and the National Cancer Institute in Bratislava, and Prof. Dr. Ugo De Giorgi at the IRCCS Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy.